ScreenerHero

GENB Generate Biomedicines, Inc.

NAS · US · Healthcare · Biotechnology · generatebiomedicines.com
13.57USD-1.67%Mkt Cap: 1.74B $P/E: —

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses pro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.74B USD
Enterprise Value1.38B USD
Revenue (TTM)26.48M USD
Gross Profit-213.80M USD
Net Income (TTM)-203.15M USD
Revenue/Share0.32 USD
Last Price13.57 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees312
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.05
PEG—
EV/EBITDA-5.52
EV/Revenue51.98
P/S66.88
P/B3.88
EPS (TTM)-2.44
EPS (Forward)-2.28
52W Range
11.0022% of range22.67
52W High22.67 USD
52W Low11.00 USD
Profitability
Gross Margin0.00%
Oper. Margin-1134.21%
EBITDA Margin0.00%
Profit Margin-636.99%
ROE32.98%
ROA-61.53%
Growth
Revenue Growth-37.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-200.62M USD
CapEx (TTM)3.51M USD
FCF Margin—
FCF Yield—
Net Debt-394.79M USD
Net Debt/EBITDA1.58
Balance Sheet
Debt/Equity-0.11
Current Ratio8.30
Quick Ratio8.08
Book Value/Sh3.56 USD
Cash/Share3.56 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.00 USD
Upside (mean)+99.0%
Target Range22.00 USD – 30.00 USD
22.00+99.0% to mean30.00
# Analysts5
Ownership
Shares Out.128.35M
Float60.45M
Insiders14.05%
Institutions77.59%
Short Interest
Short Ratio4.7d
Short % Float9.60%
Short % Out.5.59%
Shares Short7.18M
Short (prev mo.)7.29M
Technical
SMA 5015.48 (-12.4%)
SMA 20014.15 (-4.1%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)1.38M
Avg Vol (10d)1.17M
Technical Indicators
RSI (14)36.3
MACD-0.5706
MACD Signal-0.2635
MACD Hist.-0.3071
BB Upper18.04 USD
BB Middle15.49 USD
BB Lower12.95 USD
BB Width32.87%
ATR (14)0.9584 USD
Vol Ratio (20d)0.74x